GIM
BIO icon

Glenmede Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Glenmede Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76
Closed -$18.3K – 1489
2025
Q2 		$18.3K Buy
+76
New +$18K ﹤0.01% 1426

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Glenmede Investment Management's BIO Position: Q3 2025 in Review

Glenmede Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 76 shares — an estimated $18.3K sold.

Glenmede Investment Management first reported a position in BIO in Q2 2025 and held it in 1 quarter. The position peaked at $18.3K in Q2 2025. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

  • Glenmede Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 76 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $18.3K.
  • Glenmede Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's Bio-Rad Laboratories Class A position peaked at $18.3K in Q2 2025.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.